According to Cellectis's latest financial reports the company's current earnings (TTM) are -$66.01 M. In 2022 the company made an earning of -$86 M an increase over its 2021 earnings that were of -$0.13 B.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$66.01 M | -23.25% |
2022 | -$86 M | -31.26% |
2021 | -$0.13 B | 27.21% |
2020 | -$98.35 M | -14.62% |
2019 | -$0.12 B | 30.34% |
2018 | -$88.38 M | -15.02% |
2017 | -$0.11 B | 62.17% |
2016 | -$64.13 M | 185.48% |
2015 | -$22.47 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Regeneron Pharmaceuticals REGN | $4.19 B | -6,461.80% | ๐บ๐ธ USA |
uniQure QURE | -$0.31 B | 364.42% | ๐ณ๐ฑ Netherlands |
Novavax NVAX | -$0.53 B | 700.83% | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | -$79.39 M | 20.27% | ๐บ๐ธ USA |